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Objective: Randomized trials have shown that endovascular repair (EVAR) of an abdominal aortic aneurysm (AAA) has
a lower perioperative mortality than conventional open repair (OR). However, this initial survival advantage disappears
after 1 year. To make EVAR cost-effective, patient selection should be improved. The Glasgow Aneurysm Score (GAS)
estimates preoperative risk profiles that predict perioperative outcomes after OR. It was recently shown to predict
perioperative and long-term mortality after EVAR as well. Here, we applied the GAS to patients from the Dutch
Randomized Endovascular Aneurysm Repair (DREAM) trial and compared the applicability of the GAS between open
repair and EVAR.
Methods: A multicenter, randomized trial was conducted to compare OR with EVAR in 345 AAA patients. The GAS was
calculated (age  [7 points for myocardial disease]  [10 points for cerebrovascular disease]  [14 points for renal
disease]). Optimal cutoff values were determined, and test characteristics for 30-day and 2-year mortality were computed.
Results: The mean GAS was 74.7  9.3 for OR patients and 75.9  9.7 for EVAR patients. Two EVAR patients and eight
OR patients died <30 days postoperatively. The area under the receiver-operator characteristic curve (AUC) was 0.79 for
OR patients and 0.87 for EVAR patients. The optimal GAS cutoff value was 75.5 for OR and 86.5 for EVAR. By 2 years
postoperatively, 18 patients had died in both the EVAR and the OR patient groups. The AUC was 0.74 for OR patients
and 0.78 for EVAR patients. The optimal GAS cutoff value was 74.5 for OR and 77.5 for EVAR.
Conclusion: This is the first evaluation of the GAS in a randomized trial comparing AAA patients treated with OR and
EVAR. The GAS can be used for prediction of 30-day and 2-year mortality in both OR and EVAR, but in patients that
are suitable for both procedures, it is a better predictor for EVAR than for OR patients. In this study, the GAS was most
valuable in identifying low-risk patients but not very useful for the identification of the small number of high-risk
patients. ( J Vasc Surg 2008;47:277-81.)Abdominal aortic aneurysms (AAAs) are considered for
elective repair when they exceed the 55-mm threshold,
above which the risk of rupture is considered higher than
the mortality risk of surgery.1 Obviously, operative mortal-
ity is higher in patients with severe comorbidity. Endovas-
cular aneurysm repair (EVAR) was originally designed for
patients that are unfit to undergo invasive open repair
(OR). However, because of the initial positive results,
EVAR was quickly implemented in the clinical routine and
was also frequently used for low-risk patients. A drawback
of the EVAR treatment is the relatively frequent occurrence
of complications and reinterventions that arise due to in-
complete exclusion of the AAA.2 Furthermore, the devices
are expensive and therefore cost-effectiveness is not obvi-
ous.3 Another disadvantage is the need for lifelong follow-
up and the amounts of contrast and radiation involved.
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doi:10.1016/j.jvs.2007.10.018The Dutch Randomized Endovascular Aneurysm
Management (DREAM) trial and the British EVAR-1 trial
were initiated to determine which procedure is superior.4,5
The trials had very similar perioperative and mid-term
results. Although EVAR has an initial survival advantage,6,7
this benefit disappears after 1 year, and the 2-year survival
rate is approximately 90% for both procedures.8,9 The late
EVAR deaths were mainly related to cardiovascular comor-
bid conditions.
It can be assumed that some AAA patients are better off
with no surgery at all because of their high-risk profile. The
EVAR-2 trial was designed to compare the outcome of
EVAR vs an expectant policy in AAA patients who were
unfit for the conventional OR treatment.10 In summary,
after 4 years, based on intention-to-treat analysis, there was
no difference in all-cause mortality, aneurysm-related mor-
tality, or quality of life measures. The value of this trial has
been criticized because it lacked an adequate definition of
“unfit for surgery.” It therefore remains a big challenge to
clearly define and identify the high-risk AAA patient group
that presumably is better off with no surgery at all.
Scoring systems are designed to predict the risk of
specific events in individual patients. The Glasgow Aneu-
rysm Score (GAS) is a simple prediction rule for AAA
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and the presence of cardiac, cerebrovascular, renal disease,
and shock are used to classify a patient as high or low risk.
The GAS was originally designed to predict perioperative
mortality and morbidity after OR, but a recent report from
the European Collaborators on Stent-graft Techniques for
Abdominal Aortic Aneurysm Repair (EuroSTAR) showed
that the GAS may also be a good predictor of both periop-
erative and long-term results after EVAR treatment.12
Although the DREAM trial patients were considered to
be suitable for both open and endovascular repair, this
decision was not based on standardized risk-stratification
systems. Consequently, it is conceivable that patients were
included in the DREAM trial who actually had an elevated
risk of dying in the first 2 years after surgery based on a
scoring system like the GAS. This would make the indica-
tion for AAA repair questionable in these patients. Here, we
applied the GAS system to the AAA patients from the
DREAM trial to compare the predictive performance of the
GAS of 30-day and 2-year mortality between randomized
OR and EVAR patients.
METHODS
Patients. The design and methods of the trial have
previously been described in detail.4 In brief, patients with
an AAA of 50 mm, and considered suitable for both
operative methods, were referred to 24 centers in the
Netherlands and four centers in Belgium. After obtaining a
written informed consent, patients were randomly assigned
to undergo OR or EVAR. All data were submitted to the
trial coordination center (Julius Center for Health Sciences
and Primary Care, University Medical Center Utrecht, the
Netherlands). Follow-up visits were scheduled 30 days and
6, 12, 18, and 24 months after the procedure. The study
was performed according to the Declaration of Helsinki,
and the institutional review board of each participating
hospital approved the protocol.
Glasgow Aneurysm Score. The GAS was calculated
using the comorbidities described by Samy et al11: risk
score  age  (7 points for myocardial disease)  (10
points for cerebrovascular disease)  (14 points for renal
disease). The original GAS also adds 17 points for shock;
however, because this analysis was done in elective patients,
this did not apply to our study.
Myocardial disease was defined as previously docu-
mented myocardial infarction or ongoing angina pectoris,
or both. Cerebrovascular disease was defined as all grades of
stroke including transient ischemic attack. Renal disease
was defined as a serum creatinine level 150 mol/L or a
creatinine clearance 50 mL/min, or a history of acute or
chronic renal failure, or both. The elements of the GAS
were prospectively collected.
Data analysis. The association between the GAS and
30-day and 2-year mortality after OR and EVAR was
analyzed using the 2 test. To study the performance of the
GAS, we assessed its calibration and discrimination. Cali-
bration, or goodness of fit, refers to the agreement in the
individual patients between the predicted risks as assignedby the prediction rule and the actual observed frequencies
of mortality. This was evaluated with the Hosmer-Lemeshow
test, where a significant test results indicates poor model fit.
Discrimination is the ability to assign higher probabilities of
the event (death) to the patients who will actually die in the
observation period than to those patients who will survive.
This was quantified using the area under the receiver-
operator characteristic (ROC) curve (AUC). A value be-
tween 0.7 and 0.8 indicates acceptable discrimination, and
a value 0.8 indicates excellent discrimination. From the
ROC curve, we estimated the threshold that yielded the
most optimal combination of high true-positives (sensitiv-
ity) and low false-negatives (1-specificity). For this analysis,
we looked for the highest possible sensitivity while not
accepting a specificity of50%. Statistics from two-by-two
tables were calculated using the Diagnostic and Agreement
Statistics (DAG-Stat) calculator. All other statistical analysis
was performed using SPSS 11 software (SPSS Inc, Chicago,
Ill). P  .05 was considered statistically significant.
RESULTS
Of the 351 randomized patients, two died before treat-
ment (1 from a ruptured AAA before undergoing OR and
1 from a pneumonia before undergoing EVAR), and four
refused treatment (3 were originally assigned to OR and
1 was originally assigned to EVAR). The remaining 345
patients composed the treatment groups: 174 OR patients
and 171 EVAR patients. The medium GAS of OR patients
Table I. Baseline characteristics of the patients
Characteristic
OR
(n  174)
EVAR
(n  171)
Age, mean y  SD 69.5  6.8 70.7  6.6
Male sex, No. (%) 157 (90) 159 (93)
Glasgow Aneurysm Score, mean  SD 74.7  9.3 75.9  9.7
SVS/ISCVS risk factor score
(% moderate or severe)*
Diabetes mellitus 9.8 9.9
Tobacco use 54.0 64.9
Hypertension 54.0 57.9
Hyperlipidemia 53.6 47.0
Carotid disease 15.1 13.5
Cardiac disease 46.6 40.9
Renal disease 7.5 7.6
Pulmonary disease 17.8 27.5
Total, mean  SD 4.4  2.5 4.4  2.5
FEV1 (L/s)
‡ 2.6  0.7 2.5  0.7
Body mass index (kg/m2) 26.6  4.1 26.2  3.4
ASA class, No. (%)§
I (healthy status) 44 (25) 37 (22)
II (mild systemic disease) 106 (61) 119 (70)
III (severe systemic disease) 24 (14) 14 (8)
Previous abdominal surgery, No. (%) 65 (32) 43 (25)
Maximum diameter, mean mm  SD 60.0  8.5 60.6  9.0
FEV1, Forced expiratory volume in 1 second; SVS/ISCVS, Society for
Vascular Surgery/International Society of Cardiovascular Surgery; ASA,
American Society of Anesthesiologists.
*Society for Vascular Surgery/International Society for Cardiovascular Sur-
gery risk factor score (0  none; 1  mild; 2  moderate; 3  severe).was 74.7  9.3 and of EVAR patients, 75.9  9.7 (Table I).
urysm
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subsequent 2 years, six patients were lost to follow-up (5 OR
and 1 EVAR). The 2-year mortality rates therefore are based
on 169 OR and 170 EVAR patients.
Thirty-day mortality. Two EVAR patients and eight
OR patients died 30 days postoperatively (Table II, A).
Univariate analysis of the total groups showed that the GAS
was significantly associated with an increased 30-day mor-
tality in OR patients (P  .003), but not in EVAR patients
(P  .10), most likely due to the low number of events. The
Hosmer-Lemeshow test was not significant for OR (P 
.07) or EVAR (P  .55), indicating good calibration. The
ROC AUC was 0.79 for OR patients and 0.87 for EVAR
patients (Fig 1). The optimal GAS cutoff value for OR
patients was 75.5, with a sensitivity of 75.0% (95% confi-
dence interval [CI], 34.9%-96.8%) and a specificity of
54.2% (95% CI, 46.3%-62.0%; Table II, B). For EVAR
patients, the optimal cut off value was 86.5, with a sensitiv-
ity of 100% (95% CI, 15.8%-100%) and a specificity of
85.2% (95% CI, 78.9%-90.3%; Table II, B). Using these
thresholds, both treatments have a high negative-predictive
value but a low positive-predictive value.
Two-year mortality. Two years postoperatively, 18
patients had died in both the EVAR and the OR groups
(Table III, A). Univariate analysis of both groups showed
that the GAS was significantly associated with an increased
risk of 2-year mortality in both OR (P  .001) and EVAR
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Fig 1. Receiver operating characteristic (ROC) curves of the
Glasgow Aneurysm Score as a predictor of 30-day mortality after
(A) open repair (OR) and (B) endovascular aneurysm repair
(EVAR). The dots represent the cutoff values. AUC, Area under
the ROC curve (95% confidence interval). Note that the 95%
confidence intervals should be cautiously interpreted because they
are preferably based on larger sample size.13
Table II. A, Two-by-two tables of 30-day mortality after
Score cutoff values derived from Fig 1
OR 30-day GAS  75.5 GAS  75.5 Total
Alive 90 76 166
Dead 2 6 8
Total 92 82 174
GAS, Glasgow Aneurysm Score; OR, open repair; EVAR, endovascular ane(P  .001) patients. The Hosmer-Lemeshow test was notsignificant for OR (P  .44) or EVAR (P  .58), indicating
good calibration. The AUC was 0.74 for OR patients and
0.78 for EVAR patients (Fig 2). The optimal cutoff value
for OR patients was 74.5, with a sensitivity of 77.8% (95%
CI, 52.4%-93.6%) and a specificity of 52.3% (95% CI,
44.0%-60.5%; Table III, B). For EVAR patients, the opti-
mal cutoff value was 77.5, with a sensitivity of 88.9% (95%
CI, 65.3%-98.6%) and a specificity of 61.9% (95% CI,
53.6%-69.6%; Table III, B). As determined by these thresh-
olds, both treatments have a high negative-predictive value,
but a low positive-predictive value.
DISCUSSION
We studied the performance of the GAS in predicting
30-day and 2-year mortality in AAA patients who were
randomized to receive EVAR or OR. Because of the low
number of events, especially for 30-day mortality, the 95%
CIs are relatively wide for the sensitivity and the positive-
predictive value. To obtain smaller CI ranges, data from a
larger cohort are needed.
The AUCs of this study reveal several important points.
First, they show that the GAS is superior in predicting
perioperative death in EVAR-treated patients compared
with OR-treated patients. This is quite remarkable, because
the GAS was originally developed to predict surgical out-
comes after the conventional open procedure. Second, the
AUCs indicate that the GAS is suitable to predict 2-year
and endovascular repair using the Glasgow Aneurysm
EVAR 30-day GAS  86.5 GAS  86.5 Total
Alive 144 25 169
Dead 0 2 2
Total 144 27 171
repair.
Table II. B, Characteristics of the Glasgow Aneurysm
Score in predicting 30-day mortality after open and
endovascular aneurysm repair
30-day mortality
Open repair
(95% CI)
EVAR
(95% CI)
Optimal cutoff point 75.5 86.5
Sensitivity, % 75.0 (34.9-96.8) 100 (15.8-100)
Specificity, % 54.2 (46.3-62.0) 85.2 (78.9-90.3)
Positive-predictive
value, % 7.3 (2.7-15.3) 7.4 (0.9-24.3)
Negative-predictive
value, % 97.8 (92.4-99.7) 100 (97.0-100)
Likelihood ratio
positive test 1.6 (1.1-2.5) 6.8 (4.7-9.7)
Likelihood ratio
negative test* 2.2 (0.6-7.3) DNC
EVAR, Endovascular aneurysm repair; CI, confidence interval; DNC, does
not compute.
*Reciprocal.openmortality for both EVAR- and OR-treated patients. Third,
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for OR patients, this value is similar for determining peri-
operative and 2-year mortality (75.5 and 74.5). For the
EVAR-treated patients, however, there is a clear difference:
the optimal cutoff value is 86.5 for perioperative mortality
and 77.5 for 2-year mortality.
The high cutoff value for predicting perioperative death
after EVAR treatment compared with OR is not very sur-
prising and has been shown previously in a study of 5498
patients of the EUROSTAR Registry.12 Strikingly, we
found an identical optimal cutoff value for 30-day EVAR
mortality (86.5) as the previous study (86.6), which indi-
cates that our study is representative despite the low num-
ber of events.
Furthermore, we hereby validate the optimal cutoff
value reported by the researchers of EUROSTAR. The
high cutoff value confirms that this less-invasive procedure
results in better operative survival among patients with
more severe comorbidity; in other words, in patients with a
higher GAS. It also explains why the GAS is superior in
predicting perioperative mortality after EVAR compared
with OR; only those patients with severe comorbid condi-
tions are at risk of dying after EVAR. After OR, patients
with less obvious comorbidity are at risk of dying postop-
eratively as well, and therefore, the GAS performance in
predicting mortality in these patients compared with the
EVAR patients is not as good.
The observation that the cutoff value drops for the
2-year mortality prediction in EVAR patients to a value
equal for predicting 2-year mortality after OR suggests that
patients with more comorbid conditions do not benefit
from EVAR in the longer term. This was previously shown
in both the DREAM and EVAR-1 trials. The AUC remains
good, which indicates that by applying the GAS it is possi-
ble to distinguish between groups that are at high or low
risk to die of comorbid conditions 2 years after AAA
surgery.
The negative-predictive values are high compared with
the positive-predictive values. This means that in patients
who are suitable for both OR and EVAR, the GAS is better
in identifying low-risk patients than in identifying high-risk
patients. This was previously shown for OR, but not yet for
EVAR.14 It is not surprising that within a population such
as the DREAM trial, with a low prevalence of high-risk
patients, it is difficult—if not impossible—to accurately
identify high-risk patients. Therefore, testing a scoring
system for its ability to identify high-risk AAA patients that
Table III. A, Two-by-two tables of 2-year mortality after
Aneurysm Score using cutoff values derived from Fig 2
OR 2-year GAS  74.5 GAS  74.5 Total
Alive 79 72 151
Dead 4 14 18
Total 83 86 169
GAS, Glasgow Aneurysm Score; OR, open repair; EVAR, endovascular aneare better off with no surgery at all should be validated in alarge cohort of high-risk patients, like was recently done for
the Customized Probability Index15 in the patients of the
EVAR-2 trial.16
The likelihood ratios represent the relative diagnostic
gain of the application of the GAS in AAA patients. The
30-day mortality is low (1.2% EVAR, 4.6% OR), yet signif-
icant likelihood ratios were achieved. The allocation of
“high-risk” using the GAS in OR patients does not lead to
a big increase in predicted mortality rate: the positive
likelihood ratio is 1.6, which translates into an increase of
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Fig 2. Receiver-operating characteristic (ROC) curves of the
Glasgow Aneurysm Score as a predictor of 2-year mortality after
(A) open repair (OR) and (B) endovascular aneurysm repair
(EVAR). The dots represent the cutoff values. AUC, Area under
the ROC curve (95% confidence interval).
and endovascular aneurysm repair using the Glasgow
VAR 2-year GAS  77.5 GAS  77.5 Total
Alive 94 58 152
Dead 2 16 18
Total 96 74 170
repair.
Table III. B, Characteristics of the Glasgow Aneurysm
Score in predicting 2-year mortality after open and
endovascular aneurysm repair
2-year mortality
Open repair
(95% CI)
EVAR
(95% CI)
Optimal cutoff point 76.5 77.5
Sensitivity, % 77.8 (52.4-93.6) 88.9 (65.3-98.6)
Specificity, % 52.3 (44.0-60.5) 61.9 (53.6-69.6)
Positive predictive
value, % 16.0 (9.2-25.8) 21.6 (12.9-32.7)
Negative predictive
value, % 95.2 (88.1-98.7) 97.9 (92.7-99.8)
Likelihood ratio
positive test 1.6 (1.2-2.2) 2.3 (1.8-3.0)
Likelihood ratio
negative test* 2.4 (1.0-5.6) 5.6 (1.5-20.7)
EVAR, Endovascular aneurysm repair; CI, confidence interval.
*Reciprocal.open
Epredicted mortality rate from 4.6% (pretest probability) to
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ever, there is a substantial increase: the positive likelihood
ratio of 6.8 shifts the expected mortality rate from 1.2% to
7.4% in EVAR patients with a GAS 86.5.
The difference in gain of predicted mortality by apply-
ing theGAS betweenOR and EVAR patients is remarkable.
The high positive likelihood ratio of 30-day mortality for
EVAR patients possibly results from the relatively high
impact of the comorbidities on the GAS. But because the
cutoff value is high, this comorbidity only starts to play a
role in extreme circumstances. Extreme comorbidity iden-
tified by the GAS could therefore be a good starting point
from which one can discriminate between AAA patients
that are suitable for EVAR and those that are better off with
no surgery at all.
For the patients treated with OR, additional factors not
included in the GAS are apparently important in predicting
30-day mortality; therefore, applying the GAS does not
induce a major predictive gain here. The invasive surgery
also affects patients with less obvious comorbidity. The
high negative likelihood ratio for 2-year mortality of EVAR
confirms that absence of severe comorbid conditions
greatly enhances the probability of survival. For OR pa-
tients, this benefit is less pronounced and could be caused
by patient selection. Patients with significant comorbidity
who survive invasive conventional surgery may be less likely
to die than the patients with severe comorbidity who sur-
vive the relatively mild EVAR procedure.
The GAS is a good predictor of low-risk AAA patients;
however, its usefulness for identifying the individual high-
risk patient is not obvious. The GAS therefore may be
optimized by including more comorbidities, such as pul-
monary disease and diabetes, or by more stringent defini-
tions of the comorbidities now included. For instance the
scoring system might be improved by using creatinine
clearance instead of creatinine levels, and using specific
electrocardiographic deviations instead of all “cardiac dis-
ease.” However, the major driver of the GAS remains age;
and furthermore, a huge benefit of the GAS is its simplicity,
which might be lost after optimization.
CONCLUSION
We presented the first evaluation, to our knowledge, of
the GAS in a randomized trial comparing AAA patients
treated with OR or EVAR.We showed that the GAS can be
used to predict 30-day and 2-year mortality after both
treatment modalities but that its usefulness is superior in
EVAR-treated patients. In this study, the GAS was most
valuable in identifying low-risk patients but not very useful
for the identification of the small number of high-risk
patients in both the OR and EVAR patient groups.
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